ETANERCEPT TREATMENT RESULTS IN CHILDREN WITH NON-SYSTEMIC JUVENILE IDIOPATHIC ARTHRITIS: REMISSION, RECRUDESCENCE, AND ADVERSE EVENTS. RETROSPECTIVE COHORT STUDY

Background. Etanercept is a biological drug most commonly used in patients with juvenile idiopathic arthritis (JIA). The results of its use are showed in local studies.

Objective. Our aim was to evaluate the efficacy and safety of the use of etanercept in children with non-systemic JIA, to determine the predictors of remission and the risk factors for the development of exacerbations.

Methods. In a retrospective cohort study, the results of etanercept treatment (remission, exacerbations, adverse events) in children with non-systemic JIA were analyzed. The minimum follow-up period was 6 months.

Results. The period of remission within 6–36 months occurred in 77/131 (58.8%), exacerbations developed in 18/129 (14.0%) patients. Predictors of achieving remission were the age of JIA onset < 8 years [relative risk (RR) 2.05; 95% confidence interval (CI) 1.27–3.23], the age of prescribing etanercept ≤ 10 years (RR 1.7, 95% CI 1.22–2.38), the time of the disease prior to etanercept prescription < 2.5 years (RR 2.4, 95% CI 1.4–4.4), the presence of HLA-B27 antigen (RR 2.15, 95% CI 0.98–4.75; p = 0.06). The risk of exacerbations was higher in children with polyarticular JIA (RR 2.7, 95% CI 0.9–8.2; p = 0.08), whereas methotrexate therapy reduced the risk of exacerbations (RR 0.32, 95% CI 0.1–1.15; p = 0.05). Etanercept was discontinued due to primary (improvement by the ACRpedi criteria after 3 months of therapy <30%) or secondary (loss of previously achieved ≥ 30% improvement) failure in 14/152 (9.2%) patients; de novo uveitis developed in 8/152 (5.3%) patients; reactions at the injection site — in 6/152 (4.0%) patients.

Conclusion. Therapy involving etanercept is more likely to induce remission in younger patients with JIA onset at the age of 8 years and a history of less than 2.5 years. A high risk of exacerbations was noted in patients with polyarticular JIA, and low one — in those receiving methotrexate as a part of combined therapy.

1. Ravelli A, Martini A. Juvenile idiopathic arthritis. Lancet. 2007;369(9563):767–778. doi: 10.1016/S0140-6736(07)60363-8.

2. Beukelman T, Patkar NM, Saag KG, et al. 2011 American College of Rheumatology recommendations for the treatment of juvenile idiopathic arthritis: initiation and safety monitoring of therapeutic agents for the treatment of arthritis and systemic features. Arthritis Care Res (Hoboken). 2011;63(4):465–482. doi: 10.1002/acr.20460.

3. Horneff G, Klein A, Klotsche J, et al. Comparison of treatment response, remission rate and drug adherence in polyarticular juvenile idiopathic arthritis patients treated with etanercept, adalimumab or tocilizumab. Arthritis Res Ther. 2016;18(1):272. doi: 10.1186/s13075-016-1170-3.

4. Sedger LM, McDermott MF. TNF and TNF-receptors: from mediators of cell death and inflammation to therapeutic giants — past, present and future. Cytokine Growth Factor Rev. 2014;25(4): 453–472. doi: 10.1016/j.cytogfr.2014.07.016.

5. Giannini EH, Ilowite NT, Lovell DJ, et al. Long-term safety and effectiveness of etanercept in children with selected categories of juvenile idiopathic arthritis. Arthritis Rheum. 2009;60(9): 2794–2804. doi: 10.1002/art.24777.

6. Lovell DJ, Giannini EH, Reiff A, et al. Etanercept in children with polyarticular juvenile rheumatoid arthritis. N Engl J Med. 2000;342(11):763–769. doi: 10.1056/Nejm200003163421103.

7. Luca NJ, Burnett HF, Ungar WJ, et al. Cost-effectiveness analysis of first-line treatment with biologic agents in polyarticular juvenile idiopathic arthritis. Arthritis Care Res (Hoboken). 2016; 68(12):1803–1811. doi: 10.1002/acr.22903.

8. Shepherd J, Cooper K, Harris P, Picot J, Rose M. The clinical effectiveness and cost-effectiveness of abatacept, adalimumab, etanercept and tocilizumab for treating juvenile idiopathic arthritis: a systematic review and economic evaluation. Health Technol Assess. 2016;20(34):1–222. doi: 10.3310/hta20340.

9. Baranov AA, Nasonov EL, Alexeeva EI, et al. State of the specialized rheumatologic assistance for the children and adults in the Russian Federation. The project of the federal purpose oriented program «Rheumatic diseases in 2008–2012» (based on the report delivered at the presidium session of the RAMN, January 17, 2017). Current Pediatrics. 2007;6(1):6–8. (In Russ).

10. Kostik MM, Gaidar EV, Hynnes AY, et al. Methotrexate treatment may prevent uveitis onset in patients with juvenile idiopathic arthritis: experiences and subgroup analysis in a cohort with frequent methotrexate use. Clin Exp Rheumatol. 2016;34(4):714–718.

11. Zuber Z, Turowska-Heydel D, Sobczyk M, Chudek J. Prevalence of HLA-B27 antigen in patients with juvenile idiopathic arthritis. Reumatologia. 2015;53(3):125–130. doi: 10.5114/reum.2015.53133.

12. Srivastava R, Agnihotry S, Aggarwal R, et al. HLA-B27 subtypes in enthesitis-related arthritis category of juvenile idiopathic arthritis and ankylosing spondylitis in northern India. Clin Exp Rheumatol. 2015;33(6):931–935.

13. Erdes SH, Guseva IA, Krylov MYU, Benevolens kaya LI. Spondiloartropatii i subtipy HLA-B27 v nekotorykh populyatsiyakh severnoi Rossii. Ter Arkh. 1997;69(5):41–43. (In Russ).

14. Cimaz R, Marino A, Martini A. How I treat juvenile idiopathic arthritis: a state of the art review. Autoimmun Rev. 2017;16(10): 1008–1015. doi: 10.1016/j.autrev.2017.07.014.

15. Berntson L, Damgard M, Andersson-Gare B, et al. HLA-B27 predicts a more extended disease with increasing age at onset in boys with juvenile idiopathic arthritis. J Rheumatol. 2008;35(10):2055–2061.

16. Wallace CA, Ruperto N, Giannini E, et al. Preliminary criteria for clinical remission for select categories of juvenile idiopathic arthritis. J Rheumatol. 2004;31(11):2290–2294.

17. Giannini EH, Ruperto N, Ravelli A, et al. Preliminary definition of improvement in juvenile arthritis. Arthritis Rheum. 1997;40(7): 1202–1209. doi: 10.1002/art.1780400703.

18. Consolaro A, Ruperto N, Bazso A, et al. Development and validation of a composite disease activity score for juvenile idiopathic arthritis. Arthritis Rheum. 2009;61(5):658–666. doi: 10.1002/art.24516.

19. PubMed [Internet]. National Center for Biotechnology Information, U.S. National Library of Medicine [cited 2018 Mar 18]. Available from: https://www.ncbi.nlm.nih.gov/pubmed/?term=etanercept%2C+JIA% 2C+2017.

20. Horneff G, Burgos-Vargas R, Constantin T, et al. Efficacy and safety of open-label etanercept on extended oligoarticular juvenile idiopathic arthritis, enthesitis-related arthritis and psoriatic arthritis: part 1 (week 12) of the CLIPPER study. Ann Rheum Dis. 2014;73(6): 1114–1122. doi: 10.1136/annrheumdis-2012-203046.

21. Constantin T, Foeldvari I, Vojinovic J, et al. Two-year efficacy and safety of etanercept in pediatric patients with extended oligoarthritis, enthesitis-related arthritis, or psoriatic arthritis. J Rheumatol. 2016; 43(4):816–824. doi: 10.3899/jrheum.150430.

22. Minden K, Niewerth M, Zink A, et al. Long-term outcome of patients with JIA treated with etanercept, results of the biologic register JuMBO. Rheumatology (Oxford). 2012;51(8):1407–1415. doi: 10.1093/rheumatology/kes019.

23. Rothwell PM. External validity of randomised controlled trials: «to whom do the results of this trial apply?». Lancet. 2005; 365(9453):82–93. doi: 10.1016/S0140-6736(04)17670-8.

24. Schmeling H, Minden K, Foeldvari I, et al. A38: twelve years’ experience with etanercept in the treatment of juvenile idiopathic arthritis: how it has changed practice — the German Biologics JIA Registry (BiKeR). Arthritis Rheumatol. 2014;66(S3):S58. doi: 10.1002/art.38454.

25. Solari N, Palmisani E, Consolaro A, et al. Factors associated with achievement of inactive disease in children with juvenile idiopathic arthritis treated with etanercept. J Rheumatol. 2013;40(2): 192–200. doi: 10.3899/jrheum.120842.

26. Papsdorf V, Horneff G. Complete control of disease activity and remission induced by treatment with etanercept in juvenile idiopathic arthritis. Rheumatology (Oxford). 2011;50(1):214–221. doi: 10.1093/rheumatology/keq292. Erratum in Rheumatology (Oxford). 2011 Apr;50(4):814.

27. Bzarova TM. Ingibitory factora nekroza opukholi al’fa v lechenii yuvenil’nogo idiopaticheskogo artrita. [dissertation abstract] Moscow; 2015. 48 p. (In Russ).

28. Alexeeva EI, Namazova-Baranova LS, Bzarova TM, et al. Predictors of the response to etanercept in patients with juvenile idiopathic arthritis without systemic manifestations within 12 months: results of an open-label, prospective study conducted at the National Scientific and Practical Center of Children’s Health, Russia. Pediatr Rheumatol Online J. 2017;15(1):51. doi: 10.1186/s12969-017-0178-9.

29. Geikowski T, Becker I, Horneff G, German BRCSG. Predictors of response to etanercept in polyarticular-course juvenile idiopathic arthritis. Rheumatology (Oxford). 2014;53(7):1245–1249. doi: 10.1093/rheumatology/ket490.

30. Horneff G, De Bock F, Foeldvari I, et al. Safety and efficacy of combination of etanercept and methotrexate compared to treatment with etanercept only in patients with juvenile idiopathic arthritis (JIA): preliminary data from the German JIA Registry. Ann Rheum Dis. 2009;68(4):519–525. doi: 10.1136/ard.2007.087593.

31. Bzarova TM, Alexeeva EI, Valieva SI, et al. Evaluation of efficacy and safety of etanercept and etanercept + methotrexate therapy in patients with juvenile idiopathic arthritis without systemic manifestations. Current pediatrics. 2015;14(6):652–660. (In Russ.] doi: 10.15690/vsp.v14i6.1473.

32. Foeldvari I, Becker I, Horneff G. Uveitis events during adali mumab, etanercept, and methotrexate therapy in juvenile idiopathic arthritis: data from the biologics in Pediatric Rheumatology Registry. Arthritis Care Res (Hoboken). 2015;67(11):1529–1535. doi: 10.1002/acr.22613.

33. Barthel D, Ganser G, Kuester RM, et al. Inflammatory bowel disease in juvenile idiopathic arthritis patients treated with biologics. J Rheumatol. 2015;42(11):2160–2165. doi: 10.3899/jrheum.140472.

34. Chang CY, Meyer RM, Reiff AO. Impact of medication withdrawal method on flare-free survival in patients with juvenile idiopathic arthritis on combination therapy. Arthritis Care Res (Hoboken). 2015; 67(5):658–666. doi: 10.1002/acr.22477.